You are here: Industry Insights > Market News

Market News

Basic Concepts and Latest Trends in Radiation Biology: Emerging Insights and Future Directions Sadia Ajmal
September 18, 2025
This article outlines the basic concepts of radiation biology—including types of radiation, mechanisms of DNA damage, repair pathways, and biological outcomes—followed by a synthesis of the latest trends shaping the field.
InnoCare Announces Approval of HIBRUKA (Orelabrutinib) for the Treatment of Marginal Zone Lymphoma in Singapore PharmaSources
September 08, 2025
InnoCare Pharma announced today that HIBRUKA (orelabrutinib) has been approved by the Health Sciences Authority of Singapore for the treatment of adult patients with relapsed or refractory marginal zone lymphoma .
Fishing Peptide Blockbusters from Hormones Exploring the Evolution and Future of Hormone-Based Therapeutic Peptides N55.6761
September 05, 2025
Hormone-derived peptides like semaglutide ($5.16B Q1 sales) redefine drug development through long-acting engineering. Their clinical success demonstrates the transformative potential of endogenous hormones as therapeutic blueprints.
Orphan Drugs as Strategic Assets: Lifecycle Patterns, Sales Resilience, and Market Impact N55.6761
September 12, 2025
This analysis refutes the misconception of orphan drugs as niche products. Using 2025 Q1 sales data and lifecycle patterns, it demonstrates their long-term revenue resilience and strategic portfolio value.
Who Will Hold the Reins? An Analysis of Drug-Originating Countries for the US Market N55.6761
June 19, 2025
This analysis reveals a paradox: 85% of APIs for U.S. branded drugs are imported (43% from Europe). Proposed tariffs threaten global supply chains, forcing pharmaceutical companies to restructure sourcing strategies.
From Molecule to Market: Innovations Accelerating the Future of Drug Development Annie Roys
September 04, 2025
Drug discovery and development has historically been a lengthy, high risk, and costly process, often spanning more than a decade and consuming billions of dollars before a product reaches patients.
Alzheimer’s Disease: Charting the Course from Plaques to Promise Muhammad Farhan Khalid
May 28, 2025
New Tools，New Hope，New Frontier
InnoCare Announces First Patient Dosed in the Registrational Trial of BCL2 Inhibitor Mesutoclax for Treatment of BTKi-treated MCL Patients in China PharmaSources
August 21, 2025
InnoCare Pharma announced today that the first patient has been dosed in the registrational trial of B-cell lymphoma-2 (BCL2) inhibitor mesutoclax (ICP-248) for patients with BTK inhibitor treated mantle cell lymphoma (MCL) in China.
Lepu Biopharma (2157.HK) announces 2025 interim results ACN Newswire
August 21, 2025
Focusing on the field of tumor treatment, innovative biopharmaceutical company Lepu Biopharma Co., Ltd. (Lepu Biopharma or the Company, stock code: 2157.HK) announced its interim results for the first half of 2025.
Telix 2025 Half-Year Results: Strong commercial performance enables investment for long-term growth PRNewswire
August 21, 2025
Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces its financial results for the half-year ended 30 June 2025. All figures are in USD unless stated otherwise.